# Ledipasvir/Sofosbuvir for Hepatitis B Virus Infection

> **NCT03312023** · PHASE2 · COMPLETED · sponsor: **University of Maryland, Baltimore** · enrollment: 21 (actual)

## Conditions studied

- Hepatitis B

## Interventions

- **DRUG:** Ledipasvir 90 MG / Sofosbuvir 400 MG Oral Tablet [Harvoni]
- **DRUG:** Sofosbuvir 400 MG [Sovaldi]
- **DRUG:** Ledipasvir 90 MG

## Key facts

- **NCT ID:** NCT03312023
- **Lead sponsor:** University of Maryland, Baltimore
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-01
- **Primary completion:** 2020-08-10
- **Final completion:** 2021-06-30
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2021-09-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03312023

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03312023, "Ledipasvir/Sofosbuvir for Hepatitis B Virus Infection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03312023. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*